Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 3 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Korro Bio Inc. currently manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 7 distinct examiners, which indicates a one-to-one ratio of examiners to pending matters. The involvement of 3 distinct art units suggests that while the examiners are numerous, they are clustered within a relatively small number of specialized examination groups.
The busiest examiner for this portfolio is CHONG, KIMBERLY, who is responsible for 1 pending office action. Since each of the 7 distinct examiners holds exactly 1 pending action, the prosecution is perfectly decentralized across the individual examiners. This distribution means that no single examiner's habits or preferences will dominate the current prosecution landscape for the company.
Practitioners should note that the 3 distinct art units represent the primary technical silos where the company's applications are being reviewed. Navigating the current workload across 7 different individuals requires a strategy that accounts for diverse examiner perspectives while maintaining consistency across the 3 art units. The lack of concentration under any single examiner suggests that the company is experiencing a broad range of USPTO feedback.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 3 (43%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
| TRAN, CHRISTINA L | 1 | 51.6% | +48.2% |
| SHIN, DANA H | 1 | 27.0% | +27.0% |
| MEYERING, SHABANA SHABBEER | 1 | 70.6% | +42.3% |
| WHITEMAN, BRIAN A | 1 | 68.5% | +16.7% |
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17986014 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | SHIN, DANA H | 38d overdue |
| 18570938 | Methods and Compositions for ADAR-Mediated Editing | TRAN, CHRISTINA L | — |
| 17985970 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF METHYL-CPG BINDING PROTEIN 2 (MECP2) | LIPPOLIS, ALEXANDRA ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17986014 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | SHIN, DANA H | 38d overdue |
| 17985963 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF GAP JUNCTION PROTEIN BETA 2 (GJB2) | MEYERING, SHABANA SHABBEER | 6d |
| 17985978 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF RETINOCHISIN 1 (RS1) | WHITEMAN, BRIAN A | 23d |
| 18700152 | METHODS AND COMPOSITIONS FOR DISRUPTING NRF2-KEAP1 PROTEIN INTERACTION BY ADAR MEDIATED RNA EDITING | CHONG, KIMBERLY | — |
| 18570938 | Methods and Compositions for ADAR-Mediated Editing | TRAN, CHRISTINA L | — |
| 17985974 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1 (TMC1) | KONOPKA, CATHERINE ANNE | — |
| 17985970 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF METHYL-CPG BINDING PROTEIN 2 (MECP2) | LIPPOLIS, ALEXANDRA ROSE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 3 |
| 1637 | 2 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700152 | METHODS AND COMPOSITIONS FOR DISRUPTING NRF2-KEAP1 PROTEIN INTERACTION BY ADAR MEDIATED RNA EDITING | CHONG, KIMBERLY | — | §112 | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18570938 | Methods and Compositions for ADAR-Mediated Editing | TRAN, CHRISTINA L | 1637 | §102§103 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 17986014 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | SHIN, DANA H | 1635 | §103DP | Final Rejection | 38d overdue | Pending | Nov 14, 2022 |
| 17985963 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF GAP JUNCTION PROTEIN BETA 2 (GJB2) | MEYERING, SHABANA SHABBEER | 1635 | §102§103DP | Final Rejection | 6d | Pending | Nov 14, 2022 |
| 17985978 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF RETINOCHISIN 1 (RS1) | WHITEMAN, BRIAN A | 1636 | §103 | Non-Final OA | 23d | Pending | Nov 14, 2022 |
| 17985974 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1 (TMC1) | KONOPKA, CATHERINE ANNE | 1635 | §103DP | Final Rejection | — | Pending | Nov 14, 2022 |
| 17985970 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF METHYL-CPG BINDING PROTEIN 2 (MECP2) | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Nov 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial